1. Home
  2. BNC vs ALXO Comparison

BNC vs ALXO Comparison

Compare BNC & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CEA Industries Inc.

BNC

CEA Industries Inc.

HOLD

Current Price

$3.21

Market Cap

287.3M

Sector

Industrials

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$2.08

Market Cap

240.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNC
ALXO
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
287.3M
240.8M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BNC
ALXO
Price
$3.21
$2.08
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$3.50
AVG Volume (30 Days)
233.6K
1.2M
Earning Date
07-24-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
26.36
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.39
$0.41
52 Week High
$31.62
$2.66

Technical Indicators

Market Signals
Indicator
BNC
ALXO
Relative Strength Index (RSI) 54.94 60.00
Support Level $2.93 $1.99
Resistance Level $4.14 $2.30
Average True Range (ATR) 0.21 0.16
MACD 0.05 0.06
Stochastic Oscillator 73.75 95.76

Price Performance

Historical Comparison
BNC
ALXO

About BNC CEA Industries Inc.

CEA Industries Inc through its subsidiary is focused on selling environmental control and other technologies and services to the Controlled Environment Agriculture ("CEA") industry. The company provides integrated mechanical, electrical, and plumbing ("MEP") engineering design, proprietary and curated environmental control equipment, and automation offerings that serve the CEA industry. The Company has one operating segment that is dedicated to the manufacture and sale of its products.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: